This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jérôme Honnorat, MD; Paul Trouillas, MD; Charles Thivolet, MD, PhD; Michéle Aguera, PhD; Marie-Françoise Belin, PhD

Arch Neurol. 1995;52(5):462-468.

Abstract
Objective
To study the existence of autoimmunity against the cerebellum in patients with sporadic cortical cerebellar atrophy.

Design
The presence of autoantibodies against the cerebellum in the serum and cerebrospinal fluid samples that were obtained from patients with sporadic cortical cerebellar atrophy and control patients was investigated by using immunohistochemical techniques.

Setting
University hospital and research laboratory in Lyons, France.

Patients
Eight patients with cortical cerebellar atrophy that was associated with or without other neurological symptoms; 350 patients with various neurological diseases; and 33 normal, healthy subjects.

Outcome Measures
Serum and cerebrospinal fluid anti—cerebellar autoantibodies were investigated by using indirect immunofluorescence techniques in rat cerebellum. To characterize antigen labeled by patient's serum, we used an immunotrapping enzyme activity assay of glutamate decarboxylase.

Results
Serum and cerebrospinal fluid samples that were taken from one patient with sporadic cortical cerebellar atrophy associated with peripheral neuropathy and slow eye movements contained anti—glutamate decarboxylase autoantibodies.

Conclusions
These results suggest a participation of autoimmunity in the pathogenesis of some cases of sporadic cerebellar cortical atrophy and the involvement of the cerebellar -aminobutyric acid—ergic system in the pathogenesis of this disease.

Author Affiliations
From the Ataxia Research Center, Cerebrovascular Unit, Hôpital Neurologique (Drs Honnorat and Trouillas), and the Institut National de la Santé et de la Recherche Médicale (INSERM) Unity CJF-90/10 (Drs Honnorat, Aguera, and Belin) and INSERM Unity 197 (Dr Thivolet), Lyons, France.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Glutamic Acid Decarboxylase Autoimmunity With Brainstem, Extrapyramidal, and Spinal Cord Dysfunction
Pittock et al.
Mayo Clin Proc. 2006;81:1207-1214.
ABSTRACT | FULL TEXT  

Analysis of GAD65 Autoantibodies in Stiff-Person Syndrome Patients
Raju et al.
J. Immunol. 2005;175:7755-7762.
ABSTRACT | FULL TEXT  

Anti-GAD Antibodies and Periodic Alternating Nystagmus
Tilikete et al.
Arch Neurol 2005;62:1300-1303.
ABSTRACT | FULL TEXT  

Ataxia associated with Hashimoto's disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis
Selim and Drachman
J. Neurol. Neurosurg. Psychiatry 2001;71:81-87.
ABSTRACT | FULL TEXT  

Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases
Meinck et al.
J. Neurol. Neurosurg. Psychiatry 2001;71:100-103.
ABSTRACT | FULL TEXT  

Cerebellar Ataxia With Anti-Glutamic Acid Decarboxylase Antibodies: Study of 14 Patients
Honnorat et al.
Arch Neurol 2001;58:225-230.
ABSTRACT | FULL TEXT  

Cerebellar ataxia with glutamic acid decarboxylase autoantibodies
Abele et al.
Neurology 1999;52:857-857.
ABSTRACT | FULL TEXT  

Buspirone, a 5-Hydroxytryptamine1A Agonist, Is Active in Cerebellar Ataxia: Results of a Double-blind Drug Placebo Study in Patients With Cerebellar Cortical Atrophy
Trouillas et al.
Arch Neurol 1997;54:749-752.
ABSTRACT